In disease-specific sub-analyses, we found a lower survival in patients with colorectal cancer and PIK3CA mutations who, compared to wt PIK3CA patients, experienced a shorter OS-Ph1 (3.6 months vs. 10.3 months; p=0.001). This evidence concerns the gene PIK3CA and colorectal cancer.